Zacks: Brokerages Expect Allogene Therapeutics, Inc. (NASDAQ:ALLO) to Post -$0.61 EPS

Brokerages predict that Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) will post earnings per share (EPS) of ($0.61) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Allogene Therapeutics’ earnings. The lowest EPS estimate is ($0.67) and the highest is ($0.59). Allogene Therapeutics reported earnings per share of ($0.53) during the same quarter last year, which would suggest a negative year over year growth rate of 15.1%. The company is expected to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Allogene Therapeutics will report full-year earnings of ($2.59) per share for the current financial year, with EPS estimates ranging from ($2.81) to ($2.45). For the next year, analysts anticipate that the firm will report earnings of ($2.96) per share, with EPS estimates ranging from ($3.49) to ($2.56). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Allogene Therapeutics.

Allogene Therapeutics (NASDAQ:ALLO – Get Rating) last issued its earnings results on Wednesday, May 4th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.02. Allogene Therapeutics had a negative return on equity of 32.28% and a negative net margin of 148,214.64%. During the same period in the previous year, the firm earned ($0.25) earnings per share.

Several brokerages recently issued reports on ALLO. HC Wainwright reiterated a “buy” rating and set a $43.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 4th. Raymond James cut their price objective on Allogene Therapeutics from $36.00 to $13.00 in a report on Thursday, May 5th. The Goldman Sachs Group cut their price objective on Allogene Therapeutics from $20.00 to $12.00 and set a “neutral” rating for the company in a report on Monday, March 7th. William Blair reiterated an “outperform” rating on shares of Allogene Therapeutics in a report on Tuesday, March 29th. Finally, JMP Securities reiterated a “buy” rating and set a $23.00 price objective on shares of Allogene Therapeutics in a report on Monday, April 11th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $30.85.

Shares of Allogene Therapeutics stock opened at $6.78 on Monday. The stock has a market cap of $973.61 million, a PE ratio of -3.08 and a beta of 0.88. The business has a fifty day simple moving average of $8.73 and a 200-day simple moving average of $12.49. Allogene Therapeutics has a 12 month low of $6.73 and a 12 month high of $31.77.

In related news, CEO David D. Chang sold 23,648 shares of Allogene Therapeutics stock in a transaction dated Tuesday, March 15th. The stock was sold at an average price of $7.65, for a total transaction of $180,907.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Alison Moore sold 8,698 shares of Allogene Therapeutics stock in a transaction dated Tuesday, March 15th. The stock was sold at an average price of $7.63, for a total value of $66,365.74. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 57,833 shares of company stock worth $442,595. 26.30% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Primecap Management Co. CA boosted its holdings in Allogene Therapeutics by 5.2% during the first quarter. Primecap Management Co. CA now owns 4,906,266 shares of the company’s stock valued at $44,696,000 after purchasing an additional 244,451 shares in the last quarter. Jupiter Asset Management Ltd. acquired a new stake in Allogene Therapeutics during the first quarter valued at approximately $163,000. WINTON GROUP Ltd boosted its holdings in Allogene Therapeutics by 24.1% during the first quarter. WINTON GROUP Ltd now owns 30,470 shares of the company’s stock valued at $278,000 after purchasing an additional 5,911 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in Allogene Therapeutics by 29.6% during the first quarter. GSA Capital Partners LLP now owns 148,804 shares of the company’s stock valued at $1,356,000 after purchasing an additional 33,989 shares in the last quarter. Finally, InterOcean Capital Group LLC acquired a new stake in Allogene Therapeutics during the first quarter valued at approximately $109,000. 75.33% of the stock is currently owned by institutional investors.

About Allogene Therapeutics (Get Rating)

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.

Featured Articles